About Hepion Pharmaceuticals
Hepion Pharmaceuticals develops CRV431, a cyclophilin inhibitor for non-alcoholic steatohepatitis (NASH) and liver fibrosis, with applications in viral hepatitis co-infection.
📍 Location & Offices
📋 Request a Quote
Send your requirements directly to Hepion Pharmaceuticals. Response typically within 48 hours.
Company Info
TypePublic
StockHEPA (NASDAQ)
Founded2009
Employees15
Revenue$2M
HQEdison, USA